Clinical trials: Ganglioneuroblastoma
Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
This phase I/II trial studies the side effects and best dose of adavosertib and irinotecan hydrochloride in treating younger patients with solid tumors that have come back (relapsed) or that have not responded to standard therapy…
- Conditions
- Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
- Trial name
- NCT02095132
- Testing
- Adavosertib, Irinotecan Hydrochloride
- Where
- 24 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
Congenital Central Hypoventilation Syndrome
International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE
The Center for Autonomic Medicine in Pediatrics (CAMP), in collaboration with leading CCHS clinicians, scientists, and patient advocacy groups around the world has built the first International CCHS (Congenital Central…
- Trial name
- NCT03088020
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Ilya Khaytin
Neuroblastoma (NB), Ganglioneuroblastoma
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Neuroblastoma (NB) is a malignant neoplasm of the sympathetic nervous system, occurring in 1 in 8,000 live births, accounting for 6-10% of all childhood malignant neoplasms and responsible for 12-15% of mortality -, making it the…
- Trial name
- NB-NK-2026 (NCT07375563)
- Testing
- Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, irinotecan, temozolomide, dinutuximab beta, NK-cell product
- Where
- Russia
- Volunteers
- 5 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology